Neoplasms Clinical Trials
A listing of Neoplasms medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Found 188 clinical trials
Detection of cell-free circulating tumor DNA in patients with glioblastma undergoing treatment with first-line chemoradiotherapy
In multiple non-central nervous system (CNS) tumors, liquid biopsy is increasingly being utilized for non-invasive patient monitoring through blood samples containing plasma cell-free tumor DNA (cfDNA).
- 0 views
- 19 Feb, 2024
- 1 location
UPCC 02619: Adjuvant Nivolumab Or Ipilimumab + Nivolumab Determined By Pathological Response To A Single Dose Of Neoadjvuant Nivolumab
Subjects with Stage III resectable melanoma will receive adjuvant therapy, nivolumab or ipilimumab plus nivolumab, based on whether a pathologic complete response (CR) or near CR (less than 10% viable tumor cells) is achieved with one dose of nivolumab in the neoadjuvant setting followed by surgery.
- 0 views
- 19 Feb, 2024
- 1 location
A Phase II Open Label Multi-Dose Study of 89Zr-Df-IAB22M2C (CD8 PET Tracer) for Positron Emission Tomography (PET/CT) in Patients with Metastatic Solid Tumors.
If you agree to join the study, you will be asked to complete the following research procedures: a diagnostic CT or MRI or FDG-PET scan, fresh tumor biopsy (prior to and 5-7 weeks after start of cancer treatment), 89Zr-Df-IAB22M2C infusion and 89Zr-DfIAB22M2C PET/CT scans.
- 0 views
- 19 Feb, 2024
- 1 location
Physiologic MR Imaging in Distinguishing Benign from Malignant Salivary Gland Tumors
Correct diagnosis can avoid delayed treatment of cancerous tumors and the overall treatment of non-cancerous tumors, resulting in overall improvement survival and quality of life.
- 0 views
- 19 Feb, 2024
- 1 location
AMC 083 / UPCC 12716: Tissue Acquisition for Analysis of Prognostic Factors Immunology and Genetic Progression of HIV-1 Associated Malignancies
The main purpose of this study is to collect tissue from people diagnosed with HIV-associated cancer. We will use these samples to look for genetic changes associated with HIV- and other virus-related cancers. This may lead to better ways of preventing, detecting, and treating HIV-associated cancers.
- 0 views
- 19 Feb, 2024
- 1 location
UPCC 15518 / ANAM-17-21: A Phase 3 Randomized Double-Blind Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
The main purpose of this study is to learn more about how well the experimental drug, anamorelin hydrochloride (HCl), works to prevent weight loss and anorexia in patients with advanced Non-Small Cell Lung Cancer.
- 0 views
- 19 Feb, 2024
- 1 location
Trial of INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination with REGN2810 in Subjects with Newly-Diagnosed Glioblastoma (GBM)
Cemiplimab is a monoclonal antibody (protein) designed to attach to a protein called PD1. PD-1 appears on tumor cells and tumor-infiltrating immune cells, and can be used by the tumor to 'hide' from your immune system. By blocking PD-1, cemiplimab may help your immune system to attack the cancer.
- 0 views
- 19 Feb, 2024
- 1 location
Evaluation of Enhanced Gastrointestinal Cancer Screening in Lymphoma Survivors Treated with Prior Radiation Therapy
This research is being conducted to evaluate the use of enhanced gastrointestinal cancer screening in lymphoma survivors who have been treated with prior radiation therapy. We want to determine if enhanced gastrointestinal cancer screening can detect precancerous lesions and cancers in this population of patients.
- 0 views
- 19 Feb, 2024
- 1 location
UPCC 44419: Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia (AML)
The purpose of this study is to compare the effectiveness of gilteritinib to midostaurin in patients receiving standard combination chemotherapy for FLT3 AML. Eligible untreated patients with FLT3 acute myeloid leukemia (AML) between the ages of 18 and 65 will be randomized to receive gilteritinib or midostaurin during induction and …
- 0 views
- 19 Feb, 2024
- 1 location
UPCC 17518: A Phase 1 First-in-Human Open-Label Dose Escalation Study of MGD013 A Bispecific DART Protein binding PD-1 and LAG-3 in Patients with Unresectable or Metastatic Neoplasms
The primary objective of this study is to characterize the safety, tolerability, dose limiting toxicities (DLTs), and maximum tolerated dose (MTD) or maximum administered dose (MAD) (if no MTD is defined) of MGD013 when administered intravenously (IV) every 2 weeks to patients with unresectable, locally advanced or metastatic cancers.
- 0 views
- 19 Feb, 2024
- 1 location